INTRODUCTION
Although less common than primary skin cancers, cutaneous metastases (CMs) are not a rare manifestation of malignancy. A meta-analysis of 22,297 patients with solid tumors estimated that 5.3% developed CMs.
1 It is therefore estimated that in 2013, 77,166 of the 1,455,960 newly diagnosed cancers in the United States (excluding cancers of the integument or hematologic malignancies) will develop CMs.
2 This does not include 45% of patients with metastatic melanoma who also develop CMs. 3 With advances in the treatment of metastatic cancer, patients are living longer and are more likely to experience the sequelae of advanced disease, such as CMs. CMs can cause considerable morbidity, serving as a nidus for infection, bleeding, disfigurement, or pain (Appendix Fig A1, online only) . [4] [5] [6] Shimozuma et al 7 demonstrated that, among women with advanced or recurrent breast cancer, CMs were associated with the greatest negative effect on quality of life (QOL). Systemic therapy alone often has limited efficacy with CMs, but skindirected therapy has the potential to yield improved disease response and symptom palliation. [8] [9] [10] [11] [12] [13] [14] For readers unfamiliar with the various forms of skin-directed therapy discussed herein, a brief summary is provided. Electrochemotherapy (ECT) for CMs uses short electric pulses directed at the tumor to permeabilize cell membranes to increase Abbreviations: CR, complete response; ECT, electrochemotherapy; ILT, intralesional therapy; NA, not available; PDT, photodynamic therapy; PR, partial response; RT, radiotherapy; SD, stable disease;
TT, topical therapy.
‫ء‬ regression ( Table 1 ). The CR rate for all included studies was 35.5% (95% CI, 27.6% to 44.2%) according to the random effects model (heterogeneity test, Q ϭ 661.907; I 2 ϭ 93.201; P Ͻ .001; Fig 2) .
ORR
All 4,313 CMs were assessable for ORR analyses, of which 2,970 (68.9%) had ORRs. ORR was defined in 42 studies as the sum of CR plus PR, three used Ն 25% reduction from pretreatment size, and two used other definitions (Table 1) . The ORR for all studies was 60.2% (95% CI, 50.6% to 69.0%; Q ϭ 892.278; I 2 ϭ 94.621; P Ͻ .001; Fig 3) .
Secondary End Points
For response by treatment modality, CR ranged from 12.9% (95% CI, 5.4% to 27.5%) for TT to 67.8% (95% CI, 38.8% to 87.4%) for PDT (Fig 4) . By treatment modality, ORR ranged from 42.1% (95% CI, 22.3% to 64.9%) for TT to 83.8% (95% CI, 37.9% to 97.8%) for RT (Fig 5) . Three of the four combination studies used TT, with CR rate of 58.0% (95% CI, 27.7% to 83.3%) and ORR of 78.1% (95% CI, 44.1% to 94.1%).
Histology
Breast carcinoma and melanoma represented 96.8% of the CMs analyzed. They had nearly identical ORRs of 54.5% (95% CI, 48.3% to 60.7%) and 54.0% (95% CI, 48.3% to 59.7%), respectively. Of the remaining histologies, responses ranged from 50% for Kaposi's sarcoma and angiosarcoma to 83% for adenocarcinoma of unknown primary and mucosal squamous carcinoma of the head and neck (Appendix Fig A2, online only) .
Recurrence Rates
Eleven studies had extractable recurrence information for CMs after initial ORR. From the 4,313 CMs initially evaluable, 2,970 had an ORR, of which only 333 (11.2%) had recurrence information for analysis. Seventy-two lesions experienced a recurrence at time of last follow-up, with an overall recurrence rate estimated at 9.2% (95% CI, 3.7% to 21.2%; Appendix Fig A3, online only) .
Qualitative Analyses
Twenty-three studies (48.9%) used a formal toxicity scale (15 used various forms of the Common Terminology Criteria for Adverse Events, seven used WHO, and one used a custom scale); an additional three studies reported toxicity grade but did not define the scale used (Appendix Table A5 ). Treatment was well tolerated in an estimated 862 (94.2%) of 915 patients (grade Յ 2 toxicity or the equivalent). Thirty-nine patients (4.3%) experienced grade 3 local or systemic toxicity. Fourteen patients (1.5%) experienced grade 4 toxicities, three related to disseminated intravascular coagulation of unknown relation to the local ILT and seven related to various cytopenias or pleural effusion in a study that used concurrent systemic therapy with local ILT. The remaining four grade 4 toxicities were defined by exfoliative or ulcerative dermatitis.
Treatment site pain was highly treatment specific. In patients treated with ILT, pain was most commonly reported as injection site pain, which occurred in approximately 21% to 72% of patients and was often transient. Pain resolution after ECT varied across studies from near complete resolution to 49% of patients having mild pain 1 month post-treatment. 21, 22 Local pain from PDT was reported to occur in up to 95% of patients and typically resolved within 3 weeks. Multiple TT studies reported local pain but did not report duration or resolution of pain symptoms. The two RT studies did not report on pain symptoms.
QOL
Five studies used formal measures to assess QOL: three used the visual analog scale, one used a custom four-point pain scale, and one used the Rotterdam Symptom Checklist and a Body Image Scale (Appendix Table A6 ).
12,21-24 QOL results demonstrated that treatment of CMs decreased psychological distress from baseline to last follow-up. 24 ECT increased mean pain scores up to 15 minutes posttreatment and reduced pain scores below pretreatment values thereafter. 22 Combined TT and RT reduced the number of daily wound dressing changes and pain scores.
12

Publication Bias
A funnel plot of studies used to calculate CR rates (Appendix Fig  A4, online only) demonstrated asymmetry that was confirmed with Egger's regression test (P Ͻ .001), indicating the presence of publication bias. When adjusting for this bias by using the trim-and-fill method, the original observed CR rate of 35.5% increased to 61.7% (95% CI, 52.6% to 70.1%). ORRs did not appear to be subject to significant publication bias, with relative symmetry present in the funnel plot (Appendix Fig A5, online only) , confirmed with Egger's regression test (P ϭ .06).
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DISCUSSION
Decreasing symptom burden through palliative treatment can improve QOL, a goal often secondary only to improving survival in patients with cancer. 67, 68 CMs are increasingly prevalent and occur in approximately 10% of patients with metastatic cancer.
3 Some cancers have a predilection for CMs, such as breast carcinoma and melanoma, in which the rate of CMs is nearly the same as that for brain metastasis (25% and 45%, respectively).
1 Despite the prevalence of CMs, there are no guidelines for managing CMs with skin-directed therapy, and most textbooks reviewing CMs have little information on treatment.
69
This meta-analysis was designed to ascertain the efficacy of a variety of skin-directed therapies commonly used to treat CMs. The data suggest that a majority of patients will respond to skin-directed therapy, and recurrence is infrequent. Moreover, toxicity appears minimal, and data suggest an improvement in QOL. 10, 21, 24 Systemic therapy alone often has limited efficacy in CMs, with several series reporting ORRs of approximately 25%. 8, 11 The summary 60.2% ORR observed in this study clearly demonstrates the value of treating CMs with skin-directed therapy.
ECT typically involves electroporation of the cytotoxic drugs bleomycin and cisplatin. ECT has been shown to be more efficacious than ILT alone or systemic therapy alone. 28, 29 A meta-analysis of ECT for cutaneous and/or subcutaneous malignancy (including primary nonmetastatic disease) reported a crude CR rate of 59%.
9 This is comparable with our crude CR rate of ECT for CMs of 57.5% (and the estimated summary CR rate of 47.5%; Fig 3) . ECT is often performed as an inpatient procedure and most commonly requires general anesthesia; however, studies have successfully used local anesthesia alone. 22 ECT is often performed in Յ 30 minutes, but multiple treatments may be necessary. Pain is commonly reported, but general anesthesia can obviate this, and more than 90% of patients would agree to undergo another treatment if indicated. 23, 30 ECT use, especially in Europe, appears to be increasing since the publication of the European Standard Operating Procedures for Electrochemotherapy in 2006, a multicenter study standardizing the use of ECT for both primary and metastatic cancers. 23, 70, 71 PDT has been extensively studied for premalignant and primary skin cancers, with more than 40 RCTs analyzed in a systematic review in 2010. 72 However, there have been no RCTs of PDT for the treatment of CMs to date. Treatment times depend on whether an intravenous or topical photosensitizer is used but typically last less than 90 minutes. PDT is associated with treatment site pain that is mitigated by local anesthesia or oral analgesics.
RT is commonly used for the palliation of bone and brain metastases, 17, 18, 73 but only two prospective trials have assessed RT for treating CMs. 35, 36 A unique advantage of RT is the ability to penetrate to any depth by selecting an appropriate type and energy of radiation. 
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www.jco.org Treatments are typically given in several fractions over a period of weeks. Two studies used RT as part of combination therapy; high ORRs were observed, demonstrating the ability of TT or ILT to interact favorably with RT. Adverse effects primarily consist of local inflammatory symptoms. ILT typically involves the injection of cytotoxic or immunomodulatory agents directly or perilesionally to the CMs. 28,37 Despite two RCTs demonstrating superior efficacy of ECT over ILT, ILT can be a simple and effective treatment with limited adverse effects. ECT often requires general anesthesia, but ILT requires only local anesthesia. ILT often requires multiple treatment visits, with the majority of studies reporting two or more visits, and some reporting five or more visits.
TT for CMs was originally described using miltefosine, but three prospective trials with imiquimod have recently been reported. Both agents rely on enhancing the immune response against tumor cells. Most studies reported a median duration of therapy of Ն 8 weeks, with some more than 1 year. Topical monotherapy appeared to have the lowest response rates in this meta-analysis; however, response rates were improved in the three studies that combined TT with another skin-directed therapy. 12, 38, 39 We detected a less common form of publication bias among the studies analyzed; CR rates were significantly greater in larger studies. The reason for this is unclear but could be a result of factors associated with the ability to conduct a large study. Experienced institutions with a large volume of CMs were likely able to conduct larger studies and may have selected patients for successful treatment more effectively. These institutions may have also had more technical sophistication which led to improved outcomes. A related possibility is that treatment efficacy improved over time. To explore this possibility, an analysis was performed to determine whether year of publication was associated with response rates. There was no correlation between CR or ORR and year of publication (data not shown).
The analyses presented here had some limitations. Our study demonstrated significant study heterogeneity; hence, a conservative estimate of response by using a random-effects model was performed. Although all studies but one were prospective clinical trials, only 17% were RCTs. There is likely inherent bias in patient selection for particular skin-directed therapies (many of which have been shown to affect skin-directed therapy outcome), such as tumor size, 74 number of CMs, 21 and depth of invasion, 41 which we were unable to standardize and integrate into our analyses. Because of these limitations, direct comparison of outcomes by treatment modality was not performed. Studies were limited to those in the English language, which may have introduced bias. Prospective data on surgical excision of CMs exclusively was not found in our literature search (metastasectomy trials often grouped resection of lymph nodes and CM resection together). 75, 76 Finally, response criteria were heterogeneous. However,
we extensively recorded and categorized the response criteria to aid in the interpretation of the data.
In conclusion, this study was designed to elucidate the efficacy of skin-directed therapies for CMs. The results suggest that response rates were heterogeneous but high, with low recurrence rates and minimal toxicity. In addition, improvements in QOL were reported. To develop evidence-based guidelines and improve outcomes for the treatment of CM, response, criteria will need to be standardized, and RCTs will be necessary to define treatment algorithms on the basis of specific patient and CM characteristics, and an improved grasp of the potential benefits of combination or sequential skin-directed therapies is requisite. Skin-directed therapy should be considered an effective component of the cancer treatment armamentarium. 
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Study split up by histology. †Systemic therapy allowed. ‡Mean value rather than median was used. §Study split up by drug used for ILT injections. Abbreviations: ECT, electrochemotherapy; IL, intralesional; ILT, intralesional therapy; IV, intravenous; NA, not available; PDT, photodynamic therapy; RT, radiotherapy; TT, topical therapy.
Study split by histology if toxicity information was extractable by histology. †Systemic therapy allowed. ‡Study split up by drug used for IL injections. 
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